Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
University of California, Los Angeles · University of California, Berkeley · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,623
total citations
- FWCI
- 33.84
- Percentile
- 100%
- References
- 33
Citations per year
Authors
7Topics & keywords
Topics
Keywords
- Imatinib
- Myeloid leukemia
- Imatinib mesylate
- Tyrosine kinase
- Cancer research
- Protein kinase domain
- ABL
- Blast Crisis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.